LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Inicio・Lista de Acciones・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Cerrado

SectorSanidad

15.58 0.91

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

15.56

Máximo

15.62

Métricas clave
By Trading Economics
Ingresos	-130B -25B
Ventas	-99B 1.1T
P/B Media del Sector	39.974 49.888
BPA	0.21
Rentabilidad por dividendo	4.35
Margen de beneficios	-2.222
Empleados	47,455
EBITDA	-242B 214B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+35.92% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	4.35% 2.38%

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-3.7B 48B
Apertura anterior	14.67
Cierre anterior	15.58

Noticias sobre sentimiento de mercado

By Acuity

100%

320 / 344 Clasificación en Healthcare

Takeda Pharmaceutical Co Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2026, 07:52 UTC

Ganancias

Takeda Books $2.5 Billion Provision Related to Amitiza Antitrust Litigation

13 may 2026, 08:59 UTC

Ganancias

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

29 ene 2026, 07:11 UTC

Ganancias

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

5 jun 2026, 07:37 UTC

Ganancias

Takeda Books $2.5B Provision Related to Amitiza Antitrust Litigation

5 jun 2026, 07:32 UTC

Ganancias

Takeda: Year-End Dividend for Previous FY Remains Unchanged at Y100 a Share

5 jun 2026, 07:29 UTC

Ganancias

Takeda: Annual Dividend Forecast for This FY Remains Unchanged at Y204 a Share

5 jun 2026, 06:51 UTC

Ganancias

Takeda: To Seek Stay of Execution of Judgment During Pendency of Appeal

5 jun 2026, 06:51 UTC

Ganancias

Takeda: To Pursue Post-Trial Motions, Appeal

5 jun 2026, 06:50 UTC

Ganancias

Takeda: Amount of Any Liability on Company Has Not yet Been Finalized

5 jun 2026, 06:49 UTC

Ganancias

Takeda: Not Expecting Amitiza Antitrust Litigation to Materially Affect Earnings Forecasts for This FY

5 jun 2026, 06:45 UTC

Ganancias

Takeda: Earnings Revision Relates to Amitiza Antitrust Litigation

5 jun 2026, 06:40 UTC

Ganancias

Takeda: Also Booked Related Tax Benefits of Y58.4B for FY Ended March

5 jun 2026, 06:39 UTC

Ganancias

Takeda Pharmaceutical: Booked Additional Y402.5B Provision for Legal Proceedings for FY Ended March

5 jun 2026, 06:30 UTC

Ganancias

Takeda Pharmaceutical FY Loss Y152.39B Vs Net Y107.93B

5 jun 2026, 06:30 UTC

Ganancias

Takeda Pharmaceutical FY Loss Y152.39B Vs Net Y107.93B

5 jun 2026, 06:30 UTC

Ganancias

Takeda Pharmaceutical FY Loss/Shr Y96.75 Vs EPS Y68.36

5 jun 2026, 06:30 UTC

Ganancias

Takeda Pharmaceutical FY Pretax Loss Y142.36B Vs Pft Y175.08B

5 jun 2026, 06:30 UTC

Ganancias

Takeda Pharmaceutical FY Oper Pft Y6.22B Vs Pft Y342.59B

5 jun 2026, 06:30 UTC

Ganancias

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 may 2026, 06:57 UTC

Ganancias

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

13 may 2026, 06:54 UTC

Ganancias

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

13 may 2026, 06:44 UTC

Ganancias

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

13 may 2026, 06:38 UTC

Ganancias

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

13 may 2026, 06:31 UTC

Ganancias

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

13 may 2026, 06:31 UTC

Ganancias

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 may 2026, 06:31 UTC

Ganancias

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

13 may 2026, 06:31 UTC

Ganancias

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

13 may 2026, 06:31 UTC

Ganancias

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

13 may 2026, 06:31 UTC

Ganancias

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

29 ene 2026, 06:53 UTC

Ganancias

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

Comparación entre iguales

Cambio de precio

Takeda Pharmaceutical Co Ltd ADR previsión

Precio Objetivo

By TipRanks

35.92% repunte

Estimación a 12 Meses

Media 21 USD 35.92%

Máximo 21 USD

Mínimo 21 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Takeda Pharmaceutical Co Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Takeda Pharmaceutical Co Ltd ADR Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.